Marco Mor

List of Publications by Year in Descending Order

207 papers	9,825 citations	49 h-index	92 g-index
231 ext. papers	10,760 ext. citations	6.6 avg, IF	5.44 L-index

#	Paper	IF	Citations
207	NAAA-regulated lipid signaling governs the transition from acute to chronic pain. *Science Advances*, **2021**, 7, eabi8834	14.3	3
206	Palladium Catalyst Recycling for Heck-Cassar-Sonogashira Cross-Coupling Reactions in Green Solvent/Base Blend. *ChemSusChem*, **2021**, 14, 2591-2600	8.3	3
205	N-(Anilinoethyl)amide Melatonergic Ligands with Improved Water Solubility and Metabolic Stability. *ChemMedChem*, **2021**, 16, 3071-3082	3.7	3
204	Halting the FGF/FGFR axis leads to antitumor activity in Waldenström macroglobulinemia by silencing MYD88. *Blood*, **2021**, 137, 2495-2508	2.2	1
203	Different roles for the acyl chain and the amine leaving group in the substrate selectivity of -Acylethanolamine acid amidase. *Journal of Enzyme Inhibition and Medicinal Chemistry*, **2021**, 36, 1411-1423	5.6	0
202	Steps towards sustainable solid phase peptide synthesis: use and recovery of N-octyl pyrrolidone. *Green Chemistry*, **2021**, 23, 4095-4106	10	7
201	Chemical modification of NSC12 leads to a specific FGF-trap with antitumor activity in multiple myeloma. *European Journal of Medicinal Chemistry*, **2021**, 221, 113529	6.8	1
200	A sulfonyl fluoride derivative inhibits EGFR by covalent modification of the catalytic lysine. *European Journal of Medicinal Chemistry*, **2021**, 225, 113786	6.8	4
199	Free-Energy Simulations Support a Lipophilic Binding Route for Melatonin Receptors.. *Journal of Chemical Information and Modeling*, **2021**,	6.1	3
198	Design, Synthesis, and Physicochemical and Pharmacological Profiling of 7-Hydroxy-5-oxopyrazolo[4,3-]pyridine-6-carboxamide Derivatives with Antiosteoarthritic Activity In Vivo. *Journal of Medicinal Chemistry*, **2020**, 63, 7369-7391	8.3	11
197	-Acylethanolamine Acid Amidase (NAAA): Structure, Function, and Inhibition. *Journal of Medicinal Chemistry*, **2020**, 63, 7475-7490	8.3	31
196	FGF Trapping Inhibits Multiple Myeloma Growth through c-Myc Degradation-Induced Mitochondrial Oxidative Stress. *Cancer Research*, **2020**, 80, 2340-2354	10.1	18
195	Antidepressant-like effects of pharmacological inhibition of FAAH activity in socially isolated female rats. *European Neuropsychopharmacology*, **2020**, 32, 77-87	1.2	7
194	Benzisothiazolinone Derivatives as Potent Allosteric Monoacylglycerol Lipase Inhibitors That Functionally Mimic Sulfenylation of Regulatory Cysteines. *Journal of Medicinal Chemistry*, **2020**, 63, 1261-1280	8.3	3
193	Drug-gut microbiota metabolic interactions: the case of UniPR1331, selective antagonist of the Eph-ephrin system, in mice. *Journal of Pharmaceutical and Biomedical Analysis*, **2020**, 180, 113067	3.5	2
192	The GABA receptor positive allosteric modulator COR659: In vitro metabolism, in vivo pharmacokinetics in rats, synthesis and pharmacological characterization of metabolically protected derivatives. *European Journal of Pharmaceutical Sciences*, **2020**, 155, 105544	5.1	5
191	N-Acylethanolamine Acid Amidase (NAAA): Mechanism of Palmitoylethanolamide Hydrolysis Revealed by Mechanistic Simulations. *ACS Catalysis*, **2020**, 10, 11797-11813	13.1	8

190	Chiral Recognition of Flexible Melatonin Receptor Ligands Induced by Conformational Equilibria. *Molecules*, **2020**, 25,	4.8	3
189	New classes of potent heparanase inhibitors from ligand-based virtual screening. *Journal of Enzyme Inhibition and Medicinal Chemistry*, **2020**, 35, 1685-1696	5.6	4
188	Design and SAR Analysis of Covalent Inhibitors Driven by Hybrid QM/MM Simulations. *Methods in Molecular Biology*, **2020**, 2114, 307-337	1.4	7
187	The Autocrine FGF/FGFR System in both Skin and Uveal Melanoma: FGF Trapping as a Possible Therapeutic Approach. *Cancers*, **2019**, 11,	6.6	7
186	Expanding the Arsenal of FGFR Inhibitors: A Novel Chloroacetamide Derivative as a New Irreversible Agent With Anti-proliferative Activity Against FGFR1-Amplified Lung Cancer Cell Lines. *Frontiers in Oncology*, **2019**, 9, 179	5.3	23
185	Fibroblast growth factor receptor inhibitors: patent review (2015-2019). *Expert Opinion on Therapeutic Patents*, **2019**, 29, 965-977	6.8	7
184	Pharmacokinetics, pharmacodynamics and safety studies on URB937, a peripherally restricted fatty acid amide hydrolase inhibitor, in rats. *Journal of Pharmacy and Pharmacology*, **2019**, 71, 1762-1773	4.8	4
183	Overcoming the Supportive Stroma-Induced Proliferation in Waldenstrom's Macroglobulinemia By Selective Inhibition of the FGF/FGF-Receptor Axis. *Blood*, **2019**, 134, 1822-1822	2.2	
182	Balancing reactivity and antitumor activity: heteroarylthioacetamide derivatives as potent and time-dependent inhibitors of EGFR. *European Journal of Medicinal Chemistry*, **2019**, 162, 507-524	6.8	8
181	L718Q mutant EGFR escapes covalent inhibition by stabilizing a non-reactive conformation of the lung cancer drug osimertinib. *Chemical Science*, **2018**, 9, 2740-2749	9.4	51
180	Tetrahydroquinoline Ring as a Versatile Bioisostere of Tetralin for Melatonin Receptor Ligands. *Journal of Medicinal Chemistry*, **2018**, 61, 3726-3737	8.3	11
179	N-tert-butyloxycarbonyl-Phe-Leu-Phe-Leu-Phe (BOC2) inhibits the angiogenic activity of heparin-binding growth factors. *Angiogenesis*, **2018**, 21, 47-59	10.6	24
178	Conformational Propensity and Biological Studies of Proline Mutated LR Peptides Inhibiting Human Thymidylate Synthase and Ovarian Cancer Cell Growth. *Journal of Medicinal Chemistry*, **2018**, 61, 7374-7380	8.3	5
177	Novel Benzazole Derivatives Endowed with Potent Antiheparanase Activity. *Journal of Medicinal Chemistry*, **2018**, 61, 6918-6936	8.3	22
176	Identification of Bivalent Ligands with Melatonin Receptor Agonist and Fatty Acid Amide Hydrolase (FAAH) Inhibitory Activity That Exhibit Ocular Hypotensive Effect in the Rabbit. *Journal of Medicinal Chemistry*, **2018**, 61, 7902-7916	8.3	10
175	Novel Symmetrical Benzazolyl Derivatives Endowed with Potent Anti-Heparanase Activity. *Journal of Medicinal Chemistry*, **2018**, 61, 10834-10859	8.3	15
174	Repurposing of Drugs Targeting YAP-TEAD Functions. *Cancers*, **2018**, 10,	6.6	18
173	Pharmacological inhibition of FAAH activity in rodents: A promising pharmacological approach for psychological-cardiac comorbidity?. *Neuroscience and Biobehavioral Reviews*, **2017**, 74, 444-452	9	12

172	Metadynamics Simulations Distinguish Short- and Long-Residence-Time Inhibitors of Cyclin-Dependent Kinase 8. *Journal of Chemical Information and Modeling*, **2017**, 57, 159-169	6.1	37
171	Atropisomerism and Conformational Equilibria: Impact on PI3K□Inhibition of 2-((6-Amino-9H-purin-9-yl)methyl)-5-methyl-3-(o-tolyl)quinazolin-4(3H)-one (IC87114) and Its Conformationally Restricted Analogs. *Journal of Medicinal Chemistry*, **2017**, 60, 4304-4315	8.3	10
170	Synthesis and characterization of the first inhibitor of N-acylphosphatidylethanolamine phospholipase D (NAPE-PLD). *Chemical Communications*, **2017**, 53, 12814-12817	5.8	20
169	Antiproliferative and pro-apoptotic activity of melatonin analogues on melanoma and breast cancer cells. *Oncotarget*, **2017**, 8, 68338-68353	3.3	32
168	Monoglyceride lipase: Structure and inhibitors. *Chemistry and Physics of Lipids*, **2016**, 197, 13-24	3.7	38
167	Biochemical characterization of EphA2 antagonists with improved physico-chemical properties by cell-based assays and surface plasmon resonance analysis. *Biochemical Pharmacology*, **2016**, 99, 18-30	6	4
166	Free-energy studies reveal a possible mechanism for oxidation-dependent inhibition of MGL. *Scientific Reports*, **2016**, 6, 31046	4.9	6
165	L718Q Mutation as New Mechanism of Acquired Resistance to AZD9291 in EGFR-Mutated NSCLC. *Journal of Thoracic Oncology*, **2016**, 11, e121-3	8.9	110
164	Fatty Acid Amide Hydrolase (FAAH), Acetylcholinesterase (AChE), and Butyrylcholinesterase (BuChE): Networked Targets for the Development of Carbamates as Potential Anti-Alzheimer's Disease Agents. *Journal of Medicinal Chemistry*, **2016**, 59, 6387-406	8.3	46
163	Investigations on the 4-Quinolone-3-carboxylic Acid Motif. 7. Synthesis and Pharmacological Evaluation of 4-Quinolone-3-carboxamides and 4-Hydroxy-2-quinolone-3-carboxamides as High Affinity Cannabinoid Receptor 2 (CB2R) Ligands with Improved Aqueous Solubility. *Journal of Medicinal Chemistry*, **2016**, 59, 1052-67	8.3	25
162	Exploiting Free-Energy Minima to Design Novel EphA2 Protein-Protein Antagonists: From Simulation to Experiment and Return. *Chemistry - A European Journal*, **2016**, 22, 8048-52	4.8	12
161	Kinetic analysis and molecular modeling of the inhibition mechanism of roneparstat (SST0001) on human heparanase. *Glycobiology*, **2016**, 26, 640-54	5.8	51
160	Synthesis, Structural Elucidation, and Biological Evaluation of NSC12, an Orally Available Fibroblast Growth Factor (FGF) Ligand Trap for the Treatment of FGF-Dependent Lung Tumors. *Journal of Medicinal Chemistry*, **2016**, 59, 4651-63	8.3	21
159	Combined inhibition of the EGFR/AKT pathways by a novel conjugate of quinazoline with isothiocyanate. *European Journal of Medicinal Chemistry*, **2016**, 117, 283-91	6.8	11
158	Peroxide-Dependent MGL Sulfenylation Regulates 2-AG-Mediated Endocannabinoid Signaling in Brain Neurons. *Chemistry and Biology*, **2015**, 22, 619-28		25
157	A Potent Systemically Active N-Acylethanolamine Acid Amidase Inhibitor that Suppresses Inflammation and Human Macrophage Activation. *ACS Chemical Biology*, **2015**, 10, 1838-46	4.9	58
156	Fatty acid amide hydrolase inhibitors: a patent review (2009-2014). *Expert Opinion on Therapeutic Patents*, **2015**, 25, 1247-66	6.8	42
155	Long-Pentraxin 3 Derivative as a Small-Molecule FGF Trap for Cancer Therapy. *Cancer Cell*, **2015**, 28, 225-39	24.3	80

154	(5)-Cholenoyl-amino acids as selective and orally available antagonists of the Eph-ephrin system. *European Journal of Medicinal Chemistry*, **2015**, 103, 312-24	6.8	26
153	Antidepressant-like activity and cardioprotective effects of fatty acid amide hydrolase inhibitor URB694 in socially stressed Wistar Kyoto rats. *European Neuropsychopharmacology*, **2015**, 25, 2157-69	1.2	23
152	Highly Potent and Selective MT2 Melatonin Receptor Full Agonists from Conformational Analysis of 1-Benzyl-2-acylaminomethyl-tetrahydroquinolines. *Journal of Medicinal Chemistry*, **2015**, 58, 7512-25	8.3	31
151	Comparative Analysis of Virtual Screening Approaches in the Search for Novel EphA2 Receptor Antagonists. *Molecules*, **2015**, 20, 17132-51	4.8	4
150	Amino Acid Derivatives as Palmitoylethanolamide Prodrugs: Synthesis, In Vitro Metabolism and In Vivo Plasma Profile in Rats. *PLoS ONE*, **2015**, 10, e0128699	3.7	20
149	The Hippo Pathway and YAP/TAZ-TEAD Protein-Protein Interaction as Targets for Regenerative Medicine and Cancer Treatment. *Journal of Medicinal Chemistry*, **2015**, 58, 4857-73	8.3	109
148	Pushing the boundaries of vinylogous reactivity: catalytic enantioselective mukaiyama aldol reactions of highly unsaturated 2-silyloxyindoles. *Chemistry - A European Journal*, **2015**, 21, 6433-42	4.8	17
147	Pharmacokinetic and pharmacodynamic evaluation of ramelteon : an insomnia therapy. *Expert Opinion on Drug Metabolism and Toxicology*, **2015**, 11, 1145-56	5.5	10
146	Quantum mechanics/molecular mechanics modeling of covalent addition between EGFR-cysteine 797 and N-(4-anilinoquinazolin-6-yl) acrylamide. *Journal of Chemical Information and Modeling*, **2015** , 55, 589-99	6.1	33
145	Cardioprotective effects of fatty acid amide hydrolase inhibitor URB694, in a rodent model of trait anxiety. *Scientific Reports*, **2015**, 5, 18218	4.9	17
144	Analysis of illicit dietary supplements sold in the Italian market: identification of a sildenafil thioderivative as adulterant using UPLC-TOF/MS and GC/MS. *Science and Justice - Journal of the Forensic Science Society*, **2014**, 54, 228-37	2	26
143	Towards the development of 5-HT ligands combining serotonin-like and arylpiperazine moieties. *European Journal of Medicinal Chemistry*, **2014**, 80, 8-35	6.8	7
142	3-Aminoazetidin-2-one derivatives as N-acylethanolamine acid amidase (NAAA) inhibitors suitable for systemic administration. *ChemMedChem*, **2014**, 9, 1602-14	3.7	23
141	Combining ligand- and structure-based approaches for the discovery of new inhibitors of the EPHA2-ephrin-A1 interaction. *Journal of Chemical Information and Modeling*, **2014**, 54, 2621-6	6.1	11
140	ST7612AA1, a thioacetate-(lactam carboxamide) derivative selected from a novel generation of oral HDAC inhibitors. *Journal of Medicinal Chemistry*, **2014**, 57, 8358-77	8.3	31
139	Predicting the reactivity of nitrile-carrying compounds with cysteine: a combined computational and experimental study. *ACS Medicinal Chemistry Letters*, **2014**, 5, 501-5	4.3	50
138	Synthesis and characterization of new bivalent agents as melatonin- and histamine H3-ligands. *International Journal of Molecular Sciences*, **2014**, 15, 16114-33	6.3	6
137	Physical Nature of Fatty Acid Amide Hydrolase Interactions with Its Inhibitors: Testing a Simple Nonempirical Scoring Model. *Journal of Physical Chemistry B*, **2014**, 118, 14727-36	3.4	8

136	Insights in the mechanism of action and inhibition of N-acylethanolamine acid amidase by means of computational methods. *Advances in Protein Chemistry and Structural Biology*, **2014**, 96, 219-34	5.3	3
135	UniPR129 is a competitive small molecule Eph-ephrin antagonist blocking in vitro angiogenesis at low micromolar concentrations. *British Journal of Pharmacology*, **2014**, 171, 5195-208	8.6	31
134	Synthesis and structure-activity relationship studies of O-biphenyl-3-yl carbamates as peripherally restricted fatty acid amide hydrolase inhibitors. *Journal of Medicinal Chemistry*, **2013**, 56, 5917-30	8.3	22
133	Structure-based virtual screening of MT2 melatonin receptor: influence of template choice and structural refinement. *Journal of Chemical Information and Modeling*, **2013**, 53, 821-35	6.1	28
132	Synthesis and structure-activity relationship (SAR) of 2-methyl-4-oxo-3-oxetanylcarbamic acid esters, a class of potent N-acylethanolamine acid amidase (NAAA) inhibitors. *Journal of Medicinal Chemistry*, **2013**, 56, 6917-34	8.3	40
131	Long-lasting inhibition of EGFR autophosphorylation in A549 tumor cells by intracellular accumulation of non-covalent inhibitors. *Bioorganic and Medicinal Chemistry Letters*, **2013**, 23, 5290-4	2.9	2
130	Amino acid conjugates of lithocholic acid as antagonists of the EphA2 receptor. *Journal of Medicinal Chemistry*, **2013**, 56, 2936-47	8.3	40
129	Antinociceptive effects of the N-acylethanolamine acid amidase inhibitor ARN077 in rodent pain models. *Pain*, **2013**, 154, 350-360	8	85
128	Synthesis of (E)-8-(3-chlorostyryl)caffeine analogues leading to 9-deazaxanthine derivatives as dual A(2A) antagonists/MAO-B inhibitors. *Journal of Medicinal Chemistry*, **2013**, 56, 1247-61	8.3	35
127	Molecular mechanisms underlying the antitumor activity of 3-aminopropanamide irreversible inhibitors of the epidermal growth factor receptor in non-small cell lung cancer. *Neoplasia*, **2013**, 15, 61-72	6.4	12
126	Complex product composition generates risks for generic substitution also with dosage forms for intravenous administration. *International Journal of Pharmaceutics*, **2013**, 451, 50-6	6.5	3
125	Quantum mechanics/molecular mechanics modeling of fatty acid amide hydrolase reactivation distinguishes substrate from irreversible covalent inhibitors. *Journal of Medicinal Chemistry*, **2013**, 56, 2500-12	8.3	28
124	Discovery of a new class of highly potent inhibitors of acid ceramidase: synthesis and structure-activity relationship (SAR). *Journal of Medicinal Chemistry*, **2013**, 56, 3518-30	8.3	35
123	Nonempirical energetic analysis of reactivity and covalent inhibition of fatty acid amide hydrolase. *Journal of Physical Chemistry B*, **2013**, 117, 6656-66	3.4	10
122	Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Current Status and Future Perspectives in the Development of Novel Irreversible Inhibitors for the Treatment of Mutant Non-small Cell Lung Cancer. *Current Pharmaceutical Design*, **2013**, 19, 818-832	3.3	23
121	Synthesis and structure-activity relationships of amino acid conjugates of cholanic acid as antagonists of the EphA2 receptor. *Molecules*, **2013**, 18, 13043-60	4.8	12
120	Epidermal growth factor receptor tyrosine kinase inhibitors: current status and future perspectives in the development of novel irreversible inhibitors for the treatment of mutant non-small cell lung cancer. *Current Pharmaceutical Design*, **2013**, 19, 818-32	3.3	12
119	Dibasic biphenyl H3 receptor antagonists: Steric tolerance for a lipophilic side chain. *European Journal of Medicinal Chemistry*, **2012**, 48, 214-30	6.8	10

118	Divergent synthesis of novel 9-deazaxanthine derivatives via late-stage cross-coupling reactions. *Organic and Biomolecular Chemistry*, **2012**, 10, 8860-7	3.9	5
117	β-Lactones Inhibit N-acylethanolamine Acid Amidase by S-Acylation of the Catalytic N-Terminal Cysteine. *ACS Medicinal Chemistry Letters*, **2012**, 3, 422-6	4.3	35
116	MT1-selective melatonin receptor ligands: synthesis, pharmacological evaluation, and molecular dynamics investigation of N-{[(3-O-substituted)anilino]alkyl}amides. *ChemMedChem*, **2012**, 7, 1954-64	3.7	21
115	Clinical perspectives for irreversible tyrosine kinase inhibitors in cancer. *Biochemical Pharmacology*, **2012**, 84, 1388-99	6	62
114	Anxiolytic effects of the melatonin MT(2) receptor partial agonist UCM765: comparison with melatonin and diazepam. *Progress in Neuro-Psychopharmacology and Biological Psychiatry*, **2012**, 39, 318-25	5.5	46
113	Irreversible inhibition of epidermal growth factor receptor activity by 3-aminopropanamides. *Journal of Medicinal Chemistry*, **2012**, 55, 2251-64	8.3	48
112	Brain pharmacokinetics of non-imidazole biphenyl H3 receptor antagonists: a liquid chromatography/electrospray-mass spectrometry and ex vivo binding study in rats. *Chemistry and Biodiversity*, **2012**, 9, 1231-9	2.5	
111	Structure-activity relationships and mechanism of action of Eph-ephrin antagonists: interaction of cholanic acid with the EphA2 receptor. *ChemMedChem*, **2012**, 7, 1071-83	3.7	28
110	N-(2-oxo-3-oxetanyl)carbamic acid esters as N-acylethanolamine acid amidase inhibitors: synthesis and structure-activity and structure-property relationships. *Journal of Medicinal Chemistry*, **2012**, 55, 4824-36	8.3	44
109	A catalytic mechanism for cysteine N-terminal nucleophile hydrolases, as revealed by free energy simulations. *PLoS ONE*, **2012**, 7, e32397	3.7	55
108	A catalytically silent FAAH-1 variant drives anandamide transport in neurons. *Nature Neuroscience*, **2011**, 15, 64-9	25.5	134
107	Toward the definition of stereochemical requirements for MT2-selective antagonists and partial agonists by studying 4-phenyl-2-propionamidotetralin derivatives. *Journal of Medicinal Chemistry*, **2011**, 54, 8362-72	8.3	22
106	Promotion of non-rapid eye movement sleep and activation of reticular thalamic neurons by a novel MT2 melatonin receptor ligand. *Journal of Neuroscience*, **2011**, 31, 18439-52	6.6	87
105	Covalent inhibitors of fatty acid amide hydrolase: a rationale for the activity of piperidine and piperazine aryl ureas. *Journal of Medicinal Chemistry*, **2011**, 54, 6612-23	8.3	33
104	Melatonin receptor agonists: new options for insomnia and depression treatment. *CNS Neuroscience and Therapeutics*, **2011**, 17, 733-41	6.8	50
103	Biphenyl-3-yl alkylcarbamates as fatty acid amide hydrolase (FAAH) inhibitors: steric effects of N-alkyl chain on rat plasma and liver stability. *European Journal of Medicinal Chemistry*, **2011**, 46, 4466-73	6.8	16
102	Application of a SCC-DFTB QM/MM approach to the investigation of the catalytic mechanism of fatty acid amide hydrolase. *Journal of Molecular Modeling*, **2011**, 17, 2375-83	2	17
101	Bivalent ligand approach on N-{2-[(3-methoxyphenyl)methylamino]ethyl}acetamide: synthesis, binding affinity and intrinsic activity for MT(1) and MT(2) melatonin receptors. *Bioorganic and Medicinal Chemistry*, **2011**, 19, 4910-6	3.4	13

100	Metabolism of the EGFR tyrosin kinase inhibitor gefitinib by cytochrome P450 1A1 enzyme in EGFR-wild type non small cell lung cancer cell lines. *Molecular Cancer*, **2011**, 10, 143	42.1	30
99	Liquid chromatography-mass spectrometric method for determination of the non-imidazole H3-receptor antagonist UPR1056 in rat plasma. *Journal of Separation Science*, **2011**, 34, 1656-63	3.4	2
98	Understanding the role of carbamate reactivity in fatty acid amide hydrolase inhibition by QM/MM mechanistic modelling. *Chemical Communications*, **2011**, 47, 2517-9	5.8	21
97	Catalytic, asymmetric hypervinylogous Mukaiyama aldol reactions of extended furan-based silyl enolates. *Organic Letters*, **2011**, 13, 4738-41	6.2	26
96	Epidermal growth factor receptor irreversible inhibitors: chemical exploration of the cysteine-trap portion. *Mini-Reviews in Medicinal Chemistry*, **2011**, 11, 1019-30	3.2	36
95	Application of computational methods to the design of fatty acid amide hydrolase (FAAH) inhibitors based on a carbamic template structure. *Advances in Protein Chemistry and Structural Biology*, **2011**, 85, 1-26	5.3	10
94	Anandamide suppresses pain initiation through a peripheral endocannabinoid mechanism. *Nature Neuroscience*, **2010**, 13, 1265-70	25.5	250
93	Recent advances in the development of melatonin MT(1) and MT(2) receptor agonists. *Expert Opinion on Therapeutic Patents*, **2010**, 20, 1059-77	6.8	47
92	Novel irreversible epidermal growth factor receptor inhibitors by chemical modulation of the cysteine-trap portion. *Journal of Medicinal Chemistry*, **2010**, 53, 2038-50	8.3	44
91	Qualitative structure-metabolism relationships in the hydrolysis of carbamates. *Drug Metabolism Reviews*, **2010**, 42, 551-89	7	49
90	Structural Fluctuations in Enzyme-Catalyzed Reactions: Determinants of Reactivity in Fatty Acid Amide Hydrolase from Multivariate Statistical Analysis of Quantum Mechanics/Molecular Mechanics Paths. *Journal of Chemical Theory and Computation*, **2010**, 6, 2948-60	6.4	53
89	Synthesis and structure-activity relationships of N-(2-oxo-3-oxetanyl)amides as N-acylethanolamine-hydrolyzing acid amidase inhibitors. *Journal of Medicinal Chemistry*, **2010**, 53, 5770-81	8.3	49
88	Functional characterization of gefitinib uptake in non-small cell lung cancer cell lines. *Biochemical Pharmacology*, **2010**, 80, 179-87	6	27
87	Structure-property relationships of a class of carbamate-based fatty acid amide hydrolase (FAAH) inhibitors: chemical and biological stability. *ChemMedChem*, **2009**, 4, 1495-504	3.7	32
86	A second generation of carbamate-based fatty acid amide hydrolase inhibitors with improved activity in vivo. *ChemMedChem*, **2009**, 4, 1505-13	3.7	58
85	N-(Anilinoethyl)amides: design and synthesis of metabolically stable, selective melatonin receptor ligands. *ChemMedChem*, **2009**, 4, 1746-55	3.7	25
84	The collisional behavior of ESI-generated protonated molecules of some carbamate FAAH inhibitors isosteres and its relationships with biological activity. *Journal of Mass Spectrometry*, **2009**, 44, 561-5	2.2	4
83	Chiral NMR discrimination of the diastereoisomeric salts of the H3-antagonist 2-[3-(1H-imidazol-4-ylmethyl)piperidin-1-yl]-1H-benzimidazole. *Magnetic Resonance in Chemistry*, **2009**, 47, 515-8	2.1	

82	A critical cysteine residue in monoacylglycerol lipase is targeted by a new class of isothiazolinone-based enzyme inhibitors. *British Journal of Pharmacology*, **2009**, 157, 974-83	8.6	65
81	Discovery of potent and reversible monoacylglycerol lipase inhibitors. *Chemistry and Biology*, **2009**, 16, 1045-52		80
80	5-Benzylidene-hydantoins: synthesis and antiproliferative activity on A549 lung cancer cell line. *European Journal of Medicinal Chemistry*, **2009**, 44, 3471-9	6.8	34
79	Synthesis and characterization of a peripherally restricted CB1 cannabinoid antagonist, URB447, that reduces feeding and body-weight gain in mice. *Bioorganic and Medicinal Chemistry Letters*, **2009**, 19, 639-43	2.9	94
78	Selective N-acylethanolamine-hydrolyzing acid amidase inhibition reveals a key role for endogenous palmitoylethanolamide in inflammation. *Proceedings of the National Academy of Sciences of the United States of America*, **2009**, 106, 20966-71	11.5	179
77	Insights into the mechanism and inhibition of fatty acid amide hydrolase from quantum mechanics/molecular mechanics (QM/MM) modelling. *Biochemical Society Transactions*, **2009**, 37, 363-7	5.1	34
76	Pharmacological tools in endocannabinoid neurobiology. *Current Topics in Behavioral Neurosciences*, **2009**, 1, 87-110	3.4	5
75	Synthesis and quantitative structure-activity relationship of fatty acid amide hydrolase inhibitors: modulation at the N-portion of biphenyl-3-yl alkylcarbamates. *Journal of Medicinal Chemistry*, **2008**, 51, 3487-98	8.3	59
74	Dual mechanisms of action of the 5-benzylidene-hydantoin UPR1024 on lung cancer cell lines. *Molecular Cancer Therapeutics*, **2008**, 7, 361-70	6.1	55
73	Melatonin receptor agonists: SAR and applications to the treatment of sleep-wake disorders. *Current Topics in Medicinal Chemistry*, **2008**, 8, 954-68	3	54
72	Development and validation of a LC-MS method with electrospray ionization for the determination of the imidazole H3 antagonist ROS203 in rat plasma. *Journal of Pharmaceutical and Biomedical Analysis*, **2008**, 46, 200-5	3.5	1
71	Synthesis and stability in biological media of 1H-imidazole-1-carboxylates of ROS203, an antagonist of the histamine H3 receptor. *Chemistry and Biodiversity*, **2008**, 5, 140-52	2.5	7
70	Synthesis and structure-activity relationships for biphenyl H3 receptor antagonists with moderate anti-cholinesterase activity. *Bioorganic and Medicinal Chemistry*, **2008**, 16, 9911-24	3.4	29
69	Identification of productive inhibitor binding orientation in fatty acid amide hydrolase (FAAH) by QM/MM mechanistic modelling. *Chemical Communications*, **2008**, 214-6	5.8	58
68	Conformational effects in enzyme catalysis: reaction via a high energy conformation in fatty acid amide hydrolase. *Biophysical Journal*, **2007**, 92, L20-2	2.9	69
67	Antidepressant-like activity of the fatty acid amide hydrolase inhibitor URB597 in a rat model of chronic mild stress. *Biological Psychiatry*, **2007**, 62, 1103-10	7.9	278
66	Identification of a bioactive impurity in a commercial sample of 6-methyl-2-p-tolylaminobenzo[d][1,3]oxazin-4-one (URB754). *Annali Di Chimica*, **2007**, 97, 887-94		16
65	Synthesis, enantiomeric resolution, and structure-activity relationship study of a series of 10,11-dihydro-5H-dibenzo[a,d]cycloheptene MT2 receptor antagonists. *ChemMedChem*, **2007**, 2, 1741-9	3.7	11

64	Correlation between energetics of collisionally activated decompositions, interaction energy and biological potency of carbamate FAAH inhibitors. *Journal of Mass Spectrometry*, **2007**, 42, 1624-7	2.2	8
63	URB602 inhibits monoacylglycerol lipase and selectively blocks 2-arachidonoylglycerol degradation in intact brain slices. *Chemistry and Biology*, **2007**, 14, 1357-65		86
62	The fatty acid amide hydrolase inhibitor URB597 (cyclohexylcarbamic acid 3Scarbamoylbiphenyl-3-yl ester) reduces neuropathic pain after oral administration in mice. *Journal of Pharmacology and Experimental Therapeutics*, **2007**, 322, 236-42	4.7	154
61	N-(substituted-anilinoethyl)amides: design, synthesis, and pharmacological characterization of a new class of melatonin receptor ligands. *Journal of Medicinal Chemistry*, **2007**, 50, 6618-26	8.3	70
60	Synthesis and structure-activity relationships of FAAH inhibitors: cyclohexylcarbamic acid biphenyl esters with chemical modulation at the proximal phenyl ring. *ChemMedChem*, **2006**, 1, 130-9	3.7	53
59	Pharmacological characterization of hydrolysis-resistant analogs of oleoylethanolamide with potent anorexiant properties. *Journal of Pharmacology and Experimental Therapeutics*, **2006**, 318, 563-70	4.7	76
58	The fatty-acid amide hydrolase inhibitor URB597 does not affect triacylglycerol hydrolysis in rat tissues. *Pharmacological Research*, **2006**, 54, 341-4	10.2	22
57	Design and synthesis of N-(3,3-diphenylpropenyl)alkanamides as a novel class of high-affinity MT2-selective melatonin receptor ligands. *Journal of Medicinal Chemistry*, **2006**, 49, 7393-403	8.3	24
56	Pharmacological profile of the selective FAAH inhibitor KDS-4103 (URB597). *CNS Neuroscience & Therapeutics*, **2006**, 12, 21-38		278
55	Synthesis, antioxidant activity and structure-activity relationships for a new series of 2-(N-acylaminoethyl)indoles with melatonin-like cytoprotective activity. *Journal of Pineal Research*, **2006**, 40, 259-69	10.4	29
54	Dibasic non-imidazole histamine H3 receptor antagonists with a rigid biphenyl scaffold. *Bioorganic and Medicinal Chemistry Letters*, **2006**, 16, 4063-7	2.9	24
53	5-benzylidene-hydantoins as new EGFR inhibitors with antiproliferative activity. *Bioorganic and Medicinal Chemistry Letters*, **2006**, 16, 4021-5	2.9	64
52	Synthesis and biological evaluation of new non-imidazole H3-receptor antagonists of the 2-aminobenzimidazole series. *Bioorganic and Medicinal Chemistry*, **2006**, 14, 1413-24	3.4	25
51	Reassessing the melatonin pharmacophore--enantiomeric resolution, pharmacological activity, structure analysis, and molecular modeling of a constrained chiral melatonin analogue. *Bioorganic and Medicinal Chemistry*, **2006**, 14, 3383-91	3.4	26
50	MT2 selective melatonin receptor antagonists: design and structure-activity relationships. *Arkivoc*, **2006**, 2006, 8-16	0.9	12
49	Analysis of structure-activity relationships for MT2 selective antagonists by melatonin MT1 and MT2 receptor models. *Journal of Medicinal Chemistry*, **2005**, 48, 4049-60	8.3	72
48	QM/MM modelling of oleamide hydrolysis in fatty acid amide hydrolase (FAAH) reveals a new mechanism of nucleophile activation. *Chemical Communications*, **2005**, 4399-401	5.8	59
47	Validation of a histamine H3 receptor model through structure-activity relationships for classical H3 antagonists. *Bioorganic and Medicinal Chemistry*, **2005**, 13, 5647-57	3.4	39

46	Selective inhibition of 2-AG hydrolysis enhances endocannabinoid signaling in hippocampus. *Nature Neuroscience*, **2005**, 8, 1139-41	25.5	193
45	An endocannabinoid mechanism for stress-induced analgesia. *Nature*, **2005**, 435, 1108-12	50.4	586
44	Application of 3D-QSAR in the rational design of receptor ligands and enzyme inhibitors. *Chemistry and Biodiversity*, **2005**, 2, 1438-51	2.5	8
43	Characterization of the fatty acid amide hydrolase inhibitor cyclohexyl carbamic acid 3Scarbamoyl-biphenyl-3-yl ester (URB597): effects on anandamide and oleoylethanolamide deactivation. *Journal of Pharmacology and Experimental Therapeutics*, **2005**, 313, 352-8	4.7	372
42	Antidepressant-like activity and modulation of brain monoaminergic transmission by blockade of anandamide hydrolysis. *Proceedings of the National Academy of Sciences of the United States of America*, **2005**, 102, 18620-5	11.5	548
41	Imidazole H3-antagonists: relationship between structure and ex vivo binding to rat brain H3-receptors. *European Journal of Pharmaceutical Sciences*, **2004**, 23, 89-98	5.1	13
40	Cyclohexylcarbamic acid 3S or 4Ssubstituted biphenyl-3-yl esters as fatty acid amide hydrolase inhibitors: synthesis, quantitative structure-activity relationships, and molecular modeling studies. *Journal of Medicinal Chemistry*, **2004**, 47, 4998-5008	8.3	239
39	Indole-based analogs of melatonin: in vitro antioxidant and cytoprotective activities. *Journal of Pineal Research*, **2004**, 36, 95-102	10.4	38
38	Tandem mass spectrometric data-FAAH inhibitory activity relationships of some carbamic acid O-aryl esters. *Journal of Mass Spectrometry*, **2004**, 39, 1450-5	2.2	39
37	Synthesis, biological activity, QSAR and QSPR study of 2-aminobenzimidazole derivatives as potent H3-antagonists. *Bioorganic and Medicinal Chemistry*, **2004**, 12, 663-74	3.4	38
36	Synthesis, pharmacological evaluation, and structure-activity relationships of benzopyran derivatives with potent SERM activity. *Bioorganic and Medicinal Chemistry*, **2004**, 12, 3763-82	3.4	18
35	Tricyclic alkylamides as melatonin receptor ligands with antagonist or inverse agonist activity. *Journal of Medicinal Chemistry*, **2004**, 47, 4202-12	8.3	30
34	pH-partition profiles of 4-(3-oxo-1,2-benzisothiazolin-2-yl)phenyl and phenoxyalkanoic acids. *Il Farmaco*, **2003**, 58, 989-93		5
33	Modulation of anxiety through blockade of anandamide hydrolysis. *Nature Medicine*, **2003**, 9, 76-81	50.5	1211
32	Synthesis and structure-activity relationships of a series of pyrrole cannabinoid receptor agonists. *Bioorganic and Medicinal Chemistry*, **2003**, 11, 3965-73	3.4	25
31	Design, synthesis, and structure-activity relationships of alkylcarbamic acid aryl esters, a new class of fatty acid amide hydrolase inhibitors. *Journal of Medicinal Chemistry*, **2003**, 46, 2352-60	8.3	151
30	Three-dimensional quantitative structure-activity relationship studies on selected MT1 and MT2 melatonin receptor ligands: requirements for subtype selectivity and intrinsic activity modulation. *Journal of Medicinal Chemistry*, **2003**, 46, 1429-39	8.3	53
29	Synthesis and Three-Dimensional Quantitative Structure-Activity Relationship Analysis of H3 Receptor Antagonists Containing a Neutral Heterocyclic Polar Group. *Drug Design and Discovery*, **2003**, 18, 65-79		6

28	Antioxidant and cytoprotective activity of indole derivatives related to melatonin. *Advances in Experimental Medicine and Biology*, **2003**, 527, 567-75	3.6	14
27	Strategies leading to MT2 selective melatonin receptor antagonists. *Advances in Experimental Medicine and Biology*, **2003**, 527, 577-85	3.6	1
26	Synthesis and Three-Dimensional Quantitative Structure-Activity Relationship Analysis of H3 Receptor Antagonists Containing a Neutral Heterocyclic Polar Group. *Drug Design and Discovery*, **2003**, 18, 65-79		
25	Synthesis, pharmacological characterization and QSAR studies on 2-substituted indole melatonin receptor ligands. *Bioorganic and Medicinal Chemistry*, **2001**, 9, 1045-57	3.4	44
24	2-N-acylaminoalkylindoles: design and quantitative structure-activity relationship studies leading to MT2-selective melatonin antagonists. *Journal of Medicinal Chemistry*, **2001**, 44, 2900-12	8.3	53
23	Design and synthesis of melatonin receptors agonists and antagonists. *Il Farmaco*, **2000**, 55, 184-7		5
22	Statistical analysis on a series of glycine antagonists. *Il Farmaco*, **2000**, 55, 194-6		1
21	Structure-property relationships on histamine H3-antagonists: binding of phenyl-substituted alkylthioimidazole derivatives to rat plasma proteins. *Il Farmaco*, **2000**, 55, 239-45		1
20	Synthesis and biological assays of new H3-antagonists with imidazole and imidazoline polar groups. *Il Farmaco*, **2000**, 55, 27-34		8
19	Experimental and theoretical analysis of the interaction of (+/-)-cis-ketoconazole with beta-cyclodextrin in the presence of (+)-L-tartaric acid. *Journal of Pharmaceutical Sciences*, **1999**, 88, 599-607	3.9	30
18	Structure-affinity relationships of indole-based melatonin analogs. *NeuroSignals*, **1999**, 8, 15-23	1.9	11
17	Melatonin. *Current Medicinal Chemistry*, **1999**, 6, 501-18	4.3	3
16	2-[N-Acylamino(C1-C3)alkyl]indoles as MT1 melatonin receptor partial agonists, antagonists, and putative inverse agonists. *Journal of Medicinal Chemistry*, **1998**, 41, 3624-34	8.3	96
15	Modular Approach toward the Construction of the Core Motifs of Annonaceous Acetogenins and Variants Thereof. *Journal of Organic Chemistry*, **1998**, 63, 1368-1369	4.2	23
14	Melatonin receptor ligands: synthesis of new melatonin derivatives and comprehensive comparative molecular field analysis (CoMFA) study. *Journal of Medicinal Chemistry*, **1998**, 41, 3831-44	8.3	67
13	H3-receptor antagonists: synthesis and structure-activity relationships of para- and meta-substituted 4(5)-phenyl-2-[[2-[4(5)-imidazolyl]ethyl]thio]imidazoles. *Journal of Medicinal Chemistry*, **1997**, 40, 2571-8	8.3	19
12	Conformationally restrained melatonin analogues: synthesis, binding affinity for the melatonin receptor, evaluation of the biological activity, and molecular modeling study. *Journal of Medicinal Chemistry*, **1997**, 40, 1990-2002	8.3	65
11	Nuclear magnetic resonance investigations of the inclusion complexation of gliclazide with beta-cyclodextrin. *Journal of Pharmaceutical Sciences*, **1997**, 86, 72-5	3.9	29

10	Ligands of the histamine H3-receptor: new potent antagonists of the 2-thioimidazole type. *Il Farmaco*, **1997**, 52, 295-302		4
9	Plasma concentration and brain penetration of the H3-receptor antagonist thioperamide in rats. *Il Farmaco*, **1997**, 52, 457-62		8
8	Rat protein binding and cerebral phospholipid affinity of the H3-receptor antagonist thioperamide. *Journal of Pharmacy and Pharmacology*, **1996**, 48, 712-7	4.8	3
7	Biological studies on 1,2-benzisothiazole derivatives V. Antimicrobial properties of N-alkanoic, N-arylalkanoic and N-aryloxyalkanoic derivatives of 1,2-benzisothiazolin-3-one: QSAR study and genotoxicity evaluation. *Il Farmaco*, **1996**, 51, 493-501		13
6	Heteroarylaminoethyl and heteroarylthioethyl imidazoles. Synthesis and H3-receptor affinity. *European Journal of Medicinal Chemistry*, **1995**, 30, 881-889	6.8	26
5	Cholinergic agents structurally related to furtrethonium. 2. Synthesis and antimuscarinic activity of a series of N-[5-[(1Ssubstituted-acetoxy) methyl]-2-furfuryl]dialkylamines. *Journal of Medicinal Chemistry*, **1994**, 37, 4278-87	8.3	28
4	QSAR study on H3-receptor affinity of benzothiazole derivatives of thioperamide. *Il Farmaco*, **1994**, 49, 153-66		11
3	Synthesis and binding assays of H3-receptor ligands. *Il Farmaco*, **1992**, 47, 1343-65		8
2	4-(1,2-Benzisothiazol-3-yl)alkanoic and phenylalkanoic acids: synthesis and anti-inflammatory, analgesic and antipyretic activities. *Il Farmaco*, **1992**, 47, 551-65		4
1	HPLC detection of thioperamide from biological samples and its determination in rat blood and brain after systemic administration. *Il Farmaco*, **1992**, 47, 1095-103		3